Abstract
Laparoscopic gastric pacing (LGP) was first developed in the early 1990s for gastroparesis, and was also found to be effective in the treatment of obesity. Gastric electrical stimulation (GES) inhibits gastric motility and has effects on the central nervous system and the hormones related to satiety. It has been investigated for the treatment of obesity as it reduces appetite and induces early satiety.
In LGB, the application of electrical current to the stomach alters gastric myoelectrical activity without any changes in the gastrointestinal anatomy. The exact mechanism of LGP remains to be elucidated. However, potential mechanisms to assess the success of LGP might include an increased feeling of satiety as a result of reduced gastric emptying, or changes in neuropeptide levels. LGP is a minimally invasive technique that is potentially safe and effective for treating obesity; nevertheless, the selection of patients for gastric stimulation therapy appears to be an important determinant of the outcome of this treatment.
The first GES method used to treat obesity was a device called implantable gastric stimulation (IGS). It uses short pulses and has almost no effects on gastric motility (Transcend™). It changes central neuronal and hormonal activities. The second GES device (Tantalus ™) that was used clinically in patients with obesity was designed to improve gastric motility.
The third GES device used for treating obesity was called Closed-Loop Gastric Electrical Stimulation System that delivered electrical stimulation upon food intake (abiliti® system).
This chapter reviews the current status, potential mechanisms of action, operating techniques, complications, postoperative management and outcomes, and possible future applications of gastric stimulation in obesity management.
Keywords
- Laparoscopic gastric pacing
- Gastric electrical stimulation
- Implantable gastric stimulation
- Obesity
- Neuromodulation
- Laparoscopic surgery
This is a preview of subscription content, access via your institution.
References
Cigaina V, Pinato GP, Rigo V, Bevilacqua M, Ferraro F, Ischia S, Saggioro A. Gastric peristalsis control by mono situ electrical stimulation: a preliminary study. Obes Surg. 1996;6:247–9. https://doi.org/10.1381/096089296765556845.
D’Argent J. Gastric electrical stimulation as therapy of morbid obesity: preliminary results from the French study. Obes Surg. 2002;12(Suppl 1):21S–5S. https://doi.org/10.1381/096089202762552638.
Favretti F, De Luca M, Segato G, Busetto L, Ceoloni A, Magon A, Enzi G. Treatment of morbid obesity with the Transcend® Implantable Gastric Stimulator (IGS®): a prospective survey. Obes Surg. 2004;14:666–70. https://doi.org/10.1381/096089204323093462.
Greenway F, Zheng J. Electrical stimulation as treatment for obesity and diabetes. J Diabetes Sci Technol. 2007;1(2):251–9. https://doi.org/10.1177/193229680700100216.
Zhang J, Tang M, Chen JD. Gastric electrical stimulation for obesity: the need for a new device using wider pulses. Obesity (Silver Spring). 2009;17(3):474–80. https://doi.org/10.1038/oby.2008.543.
Yao SK, Ke MY, Wang ZF, Xu DB, Zhang YL. Visceral response to acute retrograde gastric electrical stimulation in healthy human. World J Gastroenterol. 2005;11(29):4541–6. https://doi.org/10.3748/wjg.v11.i29.4541.
Bohdjalian A, Prager G, Aviv R, Policker S, Schindler K, Kretschmer S, Riener R, Zacherl J, Ludvik B. One-year experience with Tantalus: a new surgical approach to treat morbid obesity. Obes Surg. 2006;16(5):627–34. https://doi.org/10.1381/096089206776945101.
Shikora S, Toouli J, Herrera MF, Kulseng B, Zulewski H, Brancatisano R, et al. Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus. J Obes. 2013;2013:245683. https://doi.org/10.1155/2013/245683.
Johnson RL, Wilson CG. A review of vagus nerve stimulation as a therapeutic intervention. J Inflamm Res. 2018;11:203–13. https://doi.org/10.2147/JIR.S163248.
Miller KA. Implantable electrical gastric stimulation to treat morbid obesity in the human: operative technique. Obes Surg. 2002;12(Suppl 1):17S–20. https://doi.org/10.1007/BF03342142.
Miller K, Hoeller E, Aigner F. The implantable gastric stimulator for obesity: an update of the European experience in the LOSS (laparoscopic obesity stimulation survey) study. Treat Endocrinol. 2006;5(1):53–8. https://doi.org/10.2165/00024677-200605010-00006.
Shikora SA. Implantable gastric stimulation - the surgical procedure: combining safety with simplicity. Obes Surg. 2004;14(Suppl 1):S9–13. https://doi.org/10.1007/BF03342132.
Callegari A, Michelini I, Squazzin C, Catona A, Klersy C. Efficacy of the SF-36 questionnaire in identifying obese patients with psychological discomfort. Obes Surg. 2005;15(2):254–60. https://doi.org/10.1381/0960892053268255.
Miller K, Höller E, Hell E. [Intragastric stimulation (IGS) for the treatment of morbid obesity.] [Article in German]. Zentralbl Chir. 2002;127:1049–54. https://doi.org/10.1055/s-2002-36378.
Bohdjalian A, Ludvik B, Guerci B, Bresler L, Renard E, Nocca D, et al. Improvement in glycemic control by gastric electrical stimulation (TANTALUS™) in overweight subjects with type 2 diabetes. Surg Endosc. 2009;23:1955–60. https://doi.org/10.1007/s00464-008-0222-4.
Mizrahi M, Ben Ya’acov AB, Ilan Y. Gastric stimulation for weight loss. World J Gastroenterol. 2012;18(19):2309–19. https://doi.org/10.3748/wjg.v18.i19.2309.
Lebovitz HE, Ludvik B, Yaniv I, et al. Metacure investigators. Treatment of patients with obese type 2 diabetes with Tantalus-DIAMOND® gastric electrical stimulation: normal triglycerides predict durable effects for at least 3 years. Horm Metab Res. 2015;47:456–62. https://doi.org/10.1055/s-0035-1548944.
Apovian CM, Shah SN, Wolfe BM, Ikramuddin S, Miller CJ, Tweden KS, et al. Two-year outcomes of vagal nerve blocking (vBloc) for the treatment of obesity in the ReCharge trial. Obes Surg. 2017;27:169–76. https://doi.org/10.1007/s11695-016-2325-7.
Shikora SA, Wolfe BM, Apovian CM, Anvari M, Sarwer DB, Gibbons RD, et al. Sustained weight loss with vagal nerve blockade but not with sham: 18-month results of the ReCharge trial. J Obes. 2015;2015:365604. https://doi.org/10.1155/2015/365604.
de Lartigue G. Role of the vagus nerve in the development and treatment of diet-induced obesity. J Physiol. 2016;594:5791–815. https://doi.org/10.1113/JP271538.
Cork SC. The role of the vagus nerve in appetite control: implications for the pathogenesis of obesity. J Neuroendocrinol. 2018;30:e12643. https://doi.org/10.1111/jne.12643.
Yao G, Kang L, Li J, Long Y, Wei H, Ferreira CA, et al. Effective weight control via an implanted self-powered vagus nerve stimulation device. Nat Commun. 2018;9(1):5349. https://doi.org/10.1038/s41467-018-07764-z.
Cigaina V. Long-term follow-up of gastric stimulation for obesity: the mestre 8-year experience. Obes Surg. 2004;14(Suppl 1):S14–22. https://doi.org/10.1007/BF03342133.
Shikora SA. Implantable gastric stimulation for the treatment of severe obesity. Obes Surg. 2004;14:545–8. https://doi.org/10.1381/096089204323013596.
Curuchi AP, Al-Juburi A, Familoni B. Gastric electrical stimulation – a ten year experience (abstract). Gastroenterology. 2004;126:W1284.
Saber AA. Gastric pacing: a new modality for the treatment of morbid obesity. J Investig Surg. 2004;17:57–9. https://doi.org/10.1080/08941930490422032.
Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of Gastroparesis. Am J Gastroenterol. 2013;108:18–37. https://doi.org/10.1038/ajg.2012.373.
Busetto L, Torres AJ, Morales-Conde S, et al. Impact of the feedback provided by a gastric electrical stimulation system on eating behavior and physical activity levels. Obesity (Silver Spring). 2017;25(3):514–21.
Maisiyiti A, Chen JD. Systematic review on gastric electrical stimulation in obesity treatment. Expert Rev Med Devices. 2019;16(10):855–61.
Paulus GF, van Avesaat M, van Rijn S, et al. Multicenter, phase 1, open prospective trial of gastric electrical stimulation for the treatment of obesity: first-in-human results with a novel implantable system. Obes Surg. 2020;30(5):1952–60.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Electronic Supplementary Material
The lead of the pacemaker is inserted into the muscle tunnel of the stomach, which positions are on the lesser curvature. An adequate length of the tunnel is mandatory, to ensure that both the electrodes are buried within the tunnel wall. The location of the generator should be on the anterior abdominal wall. The device that controls the settings (wand) is covered with a sterile cover and the system impedance is checked (MP4 16338 kb)
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Miller, K. (2021). Laparoscopic Gastric Pacing. In: Agrawal, S. (eds) Obesity, Bariatric and Metabolic Surgery. Springer, Cham. https://doi.org/10.1007/978-3-030-54064-7_49-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-54064-7_49-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-54064-7
Online ISBN: 978-3-030-54064-7
eBook Packages: MedicineMedicine